Allogeneic bone marrow transplantation in children from other than HLA-identical sibling donor

F. Locatelli, M. Bongiorno, M. Zecca, S. Giani, G. Giorgiani, R. Guagnini, P. Morandi, F. Porta, L. Nespoli, G. R. Burgio, F. Severi

Research output: Contribution to journalArticle

Abstract

Optimal allogeneic bone marrow transplantation (BMT) presupposes the use of a HLA-identical sibling as donor. Unfortunately, only about 30% of patients have an HLA-matched donor, so that the use of alternative donors has been increasingly used. We report an analysis of 13 children transplanted using an HLA-partially matched donor as source of haemopoietic stem cells. They suffered of ALL (3 patients), ANLL (1 patient), SAA (2 patients), osteopetrosis (1 patient), Wiskott-Aldrich syndrome (2 patients), severe combined immunodeficiency disease (2 patients) and familial haemophagocytic lymphohistiocytosis (2 patients). Full engraftment was obtained in all 11 of the patients who survived longer than 14 days and, globally, a moderate incidence of acute GvHD (grade II-IV) was observed in the evaluable patients (3 out of 11 with a percentage of 27%); only one patient of the six survivors more than one hundred days after BMT had severe chronic GvHD (16.6%). Four patients (31%) are actually alive and well (mean follow-up 358 days) with a mean Karnofsky score of 95%. Our data suggest that BMT from HLA-partially matched donors could represent a possible alternative therapeutic strategy in children when a compatible donor is not available. This is especially due to the reduced severity of GvHD in childhood and because of T-cell depleted marrow transplants could obtain more satisfactory results when employed in typical pediatric non-malignant disorders (i.e. immunodeficiencies) rather than in leukemia.

Original languageEnglish
Pages (from-to)124-127
Number of pages4
JournalBone Marrow Transplantation
Volume7
Issue numberSUPPL. 3
Publication statusPublished - 1991

Fingerprint

Homologous Transplantation
Bone Marrow Transplantation
Siblings
Tissue Donors
Wiskott-Aldrich Syndrome
Osteopetrosis
Severe Combined Immunodeficiency
Acute Myeloid Leukemia
Survivors
Leukemia
Stem Cells
Bone Marrow
Pediatrics

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Allogeneic bone marrow transplantation in children from other than HLA-identical sibling donor. / Locatelli, F.; Bongiorno, M.; Zecca, M.; Giani, S.; Giorgiani, G.; Guagnini, R.; Morandi, P.; Porta, F.; Nespoli, L.; Burgio, G. R.; Severi, F.

In: Bone Marrow Transplantation, Vol. 7, No. SUPPL. 3, 1991, p. 124-127.

Research output: Contribution to journalArticle

Locatelli, F, Bongiorno, M, Zecca, M, Giani, S, Giorgiani, G, Guagnini, R, Morandi, P, Porta, F, Nespoli, L, Burgio, GR & Severi, F 1991, 'Allogeneic bone marrow transplantation in children from other than HLA-identical sibling donor', Bone Marrow Transplantation, vol. 7, no. SUPPL. 3, pp. 124-127.
Locatelli, F. ; Bongiorno, M. ; Zecca, M. ; Giani, S. ; Giorgiani, G. ; Guagnini, R. ; Morandi, P. ; Porta, F. ; Nespoli, L. ; Burgio, G. R. ; Severi, F. / Allogeneic bone marrow transplantation in children from other than HLA-identical sibling donor. In: Bone Marrow Transplantation. 1991 ; Vol. 7, No. SUPPL. 3. pp. 124-127.
@article{705e422ffd8940079152c03c8979d072,
title = "Allogeneic bone marrow transplantation in children from other than HLA-identical sibling donor",
abstract = "Optimal allogeneic bone marrow transplantation (BMT) presupposes the use of a HLA-identical sibling as donor. Unfortunately, only about 30{\%} of patients have an HLA-matched donor, so that the use of alternative donors has been increasingly used. We report an analysis of 13 children transplanted using an HLA-partially matched donor as source of haemopoietic stem cells. They suffered of ALL (3 patients), ANLL (1 patient), SAA (2 patients), osteopetrosis (1 patient), Wiskott-Aldrich syndrome (2 patients), severe combined immunodeficiency disease (2 patients) and familial haemophagocytic lymphohistiocytosis (2 patients). Full engraftment was obtained in all 11 of the patients who survived longer than 14 days and, globally, a moderate incidence of acute GvHD (grade II-IV) was observed in the evaluable patients (3 out of 11 with a percentage of 27{\%}); only one patient of the six survivors more than one hundred days after BMT had severe chronic GvHD (16.6{\%}). Four patients (31{\%}) are actually alive and well (mean follow-up 358 days) with a mean Karnofsky score of 95{\%}. Our data suggest that BMT from HLA-partially matched donors could represent a possible alternative therapeutic strategy in children when a compatible donor is not available. This is especially due to the reduced severity of GvHD in childhood and because of T-cell depleted marrow transplants could obtain more satisfactory results when employed in typical pediatric non-malignant disorders (i.e. immunodeficiencies) rather than in leukemia.",
author = "F. Locatelli and M. Bongiorno and M. Zecca and S. Giani and G. Giorgiani and R. Guagnini and P. Morandi and F. Porta and L. Nespoli and Burgio, {G. R.} and F. Severi",
year = "1991",
language = "English",
volume = "7",
pages = "124--127",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Allogeneic bone marrow transplantation in children from other than HLA-identical sibling donor

AU - Locatelli, F.

AU - Bongiorno, M.

AU - Zecca, M.

AU - Giani, S.

AU - Giorgiani, G.

AU - Guagnini, R.

AU - Morandi, P.

AU - Porta, F.

AU - Nespoli, L.

AU - Burgio, G. R.

AU - Severi, F.

PY - 1991

Y1 - 1991

N2 - Optimal allogeneic bone marrow transplantation (BMT) presupposes the use of a HLA-identical sibling as donor. Unfortunately, only about 30% of patients have an HLA-matched donor, so that the use of alternative donors has been increasingly used. We report an analysis of 13 children transplanted using an HLA-partially matched donor as source of haemopoietic stem cells. They suffered of ALL (3 patients), ANLL (1 patient), SAA (2 patients), osteopetrosis (1 patient), Wiskott-Aldrich syndrome (2 patients), severe combined immunodeficiency disease (2 patients) and familial haemophagocytic lymphohistiocytosis (2 patients). Full engraftment was obtained in all 11 of the patients who survived longer than 14 days and, globally, a moderate incidence of acute GvHD (grade II-IV) was observed in the evaluable patients (3 out of 11 with a percentage of 27%); only one patient of the six survivors more than one hundred days after BMT had severe chronic GvHD (16.6%). Four patients (31%) are actually alive and well (mean follow-up 358 days) with a mean Karnofsky score of 95%. Our data suggest that BMT from HLA-partially matched donors could represent a possible alternative therapeutic strategy in children when a compatible donor is not available. This is especially due to the reduced severity of GvHD in childhood and because of T-cell depleted marrow transplants could obtain more satisfactory results when employed in typical pediatric non-malignant disorders (i.e. immunodeficiencies) rather than in leukemia.

AB - Optimal allogeneic bone marrow transplantation (BMT) presupposes the use of a HLA-identical sibling as donor. Unfortunately, only about 30% of patients have an HLA-matched donor, so that the use of alternative donors has been increasingly used. We report an analysis of 13 children transplanted using an HLA-partially matched donor as source of haemopoietic stem cells. They suffered of ALL (3 patients), ANLL (1 patient), SAA (2 patients), osteopetrosis (1 patient), Wiskott-Aldrich syndrome (2 patients), severe combined immunodeficiency disease (2 patients) and familial haemophagocytic lymphohistiocytosis (2 patients). Full engraftment was obtained in all 11 of the patients who survived longer than 14 days and, globally, a moderate incidence of acute GvHD (grade II-IV) was observed in the evaluable patients (3 out of 11 with a percentage of 27%); only one patient of the six survivors more than one hundred days after BMT had severe chronic GvHD (16.6%). Four patients (31%) are actually alive and well (mean follow-up 358 days) with a mean Karnofsky score of 95%. Our data suggest that BMT from HLA-partially matched donors could represent a possible alternative therapeutic strategy in children when a compatible donor is not available. This is especially due to the reduced severity of GvHD in childhood and because of T-cell depleted marrow transplants could obtain more satisfactory results when employed in typical pediatric non-malignant disorders (i.e. immunodeficiencies) rather than in leukemia.

UR - http://www.scopus.com/inward/record.url?scp=0025869510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025869510&partnerID=8YFLogxK

M3 - Article

C2 - 1855074

AN - SCOPUS:0025869510

VL - 7

SP - 124

EP - 127

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - SUPPL. 3

ER -